ResMed price target raised to $182 from $181 at RBC Capital

RBC Capital raised the firm’s price target on ResMed to $182 from $181 and keeps a Sector Perform rating on the shares. The company delivered a solid result which demonstrated revenues continued to rise, gross margins have inflected and operating leverage has begun to benefit the bottom line, the analyst tells investors in a research note.